TREXAVIVE is a subcutaneous therapy designed to treat major depressive disorder, PTSD, and suicidality. It works by targeting both GABA and opioid pathways — offering a dualmechanism approach that is fast-acting, non dissociative, and non-sedating.
Now funded by the Department of Veterans’ Affairs (DVA) for
eligible patients.
TRD, PTSD, suicidality
GABAergic + opioid modulation
Subcutaneous injection
No sedation – No dissociation – No addiction liability
What is TREXAVIVE? A new treatment designed to help when others haven’t. It targets key brain systems involved in depression, without the side effects often seen in traditional medications.
What to do next – Ask your doctor or psychiatrist about TREXAVIVE – You may be eligible if you’re living with major depression, PTSD or suicidality.
DVA-Funded Access TREXAVIVE is available to eligible
veterans through the Department of Veterans’ Affairs.
How to access it – Speak to your GP or mental health
provider – Provide your DVA details for assessment.
TREXAVIVE is Trexapharm’s lead therapy — a purpose-built, repurposed intervention for high-need mental health conditions. Already approved for use with DVA funding, its trajectory reflects our broader platform opportunity.